Neuronetics (STIM) to Release Earnings on Tuesday

Neuronetics (NASDAQ:STIM) is projected to post its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect Neuronetics to post earnings of ($0.12) per share and revenue of $40.8440 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 17, 2026 at 8:30 AM ET.

Neuronetics Stock Down 3.9%

Shares of NASDAQ STIM opened at $1.24 on Tuesday. The business has a 50-day moving average price of $1.67 and a 200 day moving average price of $2.30. The stock has a market cap of $84.93 million, a PE ratio of -1.51 and a beta of 0.78. The company has a quick ratio of 2.09, a current ratio of 2.24 and a debt-to-equity ratio of 2.09. Neuronetics has a 52-week low of $1.20 and a 52-week high of $5.92.

Analysts Set New Price Targets

Several research firms have recently weighed in on STIM. Weiss Ratings reissued a “sell (e+)” rating on shares of Neuronetics in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Neuronetics from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Insider Activity

In other news, CEO Keith J. Sullivan sold 40,976 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $1.55, for a total value of $63,512.80. Following the transaction, the chief executive officer owned 1,567,012 shares of the company’s stock, valued at approximately $2,428,868.60. The trade was a 2.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 92,428 shares of company stock valued at $148,060 over the last quarter. Insiders own 9.80% of the company’s stock.

Hedge Funds Weigh In On Neuronetics

A number of hedge funds and other institutional investors have recently bought and sold shares of STIM. National Bank of Canada FI raised its position in Neuronetics by 27.5% during the 3rd quarter. National Bank of Canada FI now owns 31,880 shares of the company’s stock worth $87,000 after buying an additional 6,880 shares during the last quarter. Royal Bank of Canada boosted its position in shares of Neuronetics by 17.7% during the 4th quarter. Royal Bank of Canada now owns 47,233 shares of the company’s stock worth $65,000 after purchasing an additional 7,099 shares in the last quarter. Barclays PLC grew its holdings in shares of Neuronetics by 19.2% in the 4th quarter. Barclays PLC now owns 61,606 shares of the company’s stock worth $85,000 after acquiring an additional 9,941 shares during the period. Squarepoint Ops LLC grew its stake in Neuronetics by 20.0% in the 3rd quarter. Squarepoint Ops LLC now owns 62,458 shares of the company’s stock valued at $171,000 after acquiring an additional 10,423 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Neuronetics during the 2nd quarter valued at $37,000. 53.59% of the stock is currently owned by hedge funds and other institutional investors.

About Neuronetics

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.